ExpreS2ion Biotech Holding AB (FRA:5JD0) PEG Ratio: 0.00 (As of Jul. 07, 2026)


FRA:5JD0 ExpreS2ion Biotech Holding AB FRA:5JD0
25 GF Score
Price €0.11
GF Value €0.34
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB PEG Ratio?

ExpreS2ion Biotech Holding AB FRA:5JD0 -0.90% 25 PEG Ratio is 0.00 as of Jul. 07, 2026. GuruFocus rates FRA:5JD0 with a GF Score™ of 25/100 and a GF Value™ of €0.34 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 94 Biotechnology companies, ExpreS2ion Biotech Holding AB ranks worse than 1063828.72% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, ExpreS2ion Biotech Holding AB's PE Ratio without NRI is 0.00. ExpreS2ion Biotech Holding AB's 5-Year EBITDA growth rate is 20.50%. Therefore, ExpreS2ion Biotech Holding AB's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for ExpreS2ion Biotech Holding AB's PEG Ratio or its related term are showing as below:



FRA:5JD0's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.02
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


ExpreS2ion Biotech Holding AB  (FRA:5JD0) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


ExpreS2ion Biotech Holding AB PEG Ratio Related Terms


ExpreS2ion Biotech Holding AB PEG Ratio Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB PEG Ratio Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:5JD0 vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's PEG Ratio distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's PEG Ratio falls into.


FRA:5JD0
25GF Score
ExpreS2ion Biotech Holding AB FRA:5JD0
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

ExpreS2ion Biotech Holding AB's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/20.50
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a PEG Ratio of 0.00 as of Jul. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on ExpreS2ion Biotech Holding AB and its competitors. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #999999 out of 94 companies in the Biotechnology industry.
Is ExpreS2ion Biotech Holding AB's PEG Ratio too high?
ExpreS2ion Biotech Holding AB's current PEG Ratio is 0.00. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #999999 out of 94 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #999999 out of 94 companies for PEG Ratio. This places ExpreS2ion Biotech Holding AB in the lower half of its industry. The industry median PEG Ratio is 2.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 2.02, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on ExpreS2ion Biotech Holding AB and its competitors. For the Biotechnology industry, the median PEG Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (FRA:5JD0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.34, compared to a current price of €0.11 — trading 67.5% below its estimated fair value. The current PEG Ratio is 0.00. ExpreS2ion Biotech Holding AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current PEG Ratio is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of €0.11 is trading 67.5% below its estimated GF Value™ of €0.34. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for FRA:5JD0:

  • PEG Ratio: 0.00
  • GF Value™: €0.34 vs. price of €0.11 (67.5% below fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ExpreS2ion Biotech Holding AB Business Description

Other Exchanges EXPRS2:Sweden
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
25GF Score

Get the complete analysis for FRA:5JD0

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.34
GF Value